Vis enkel innførsel

dc.contributor.authorMadland, Eva
dc.contributor.authorFelipe Guerrero-Garzón, Jaime
dc.contributor.authorZehl, Martin
dc.contributor.authorSingh, Madhurendra
dc.contributor.authorRezaei, Shiva
dc.contributor.authorAachmann, Finn Lillelund
dc.contributor.authorCourtade, Gaston
dc.contributor.authorUrban, Ernst
dc.contributor.authorRückert, Christian
dc.contributor.authorBusche, Tobias
dc.contributor.authorKalinowski, Jörn
dc.contributor.authorCao, Yan-Ru
dc.contributor.authorJiang, Yi
dc.contributor.authorJiang, Cheng-lin
dc.contributor.authorSelivanova, Galina
dc.contributor.authorZotchev, Sergey
dc.date.accessioned2021-01-20T09:15:14Z
dc.date.available2021-01-20T09:15:14Z
dc.date.created2020-11-10T18:55:09Z
dc.date.issued2020
dc.identifier.issn2589-0042
dc.identifier.urihttps://hdl.handle.net/11250/2723827
dc.description.abstractHeterologous expression of a biosynthesis gene cluster from Amycolatopsis sp. resulted in the discovery of two unique class IV lasso peptides, felipeptins A1 and A2. A mixture of felipeptins stimulated proliferation of cancer cells, while having no such effect on the normal cells. Detailed investigation revealed, that pre-treatment of cancer cells with a mixture of felipeptins resulted in downregulation of the tumor suppressor Rb, making the cancer cells to proliferate faster. Pre-treatment with felipeptins made cancer cells considerably more sensitive to the anticancer agent doxorubicin and re-sensitized doxorubicin-resistant cells to this drug. Structural characterization and binding experiments showed an interaction between felipeptins resulting in complex formation, which explains their synergistic effect. This discovery may open an alternative avenue in cancer treatment, helping to eliminate quiescent cells that often lead to cancer relapse.en_US
dc.language.isoengen_US
dc.publisherCell Pressen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.no*
dc.titleClass IV lasso peptides synergistically induce proliferation of cancer cells and sensitize them to doxorubicinen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.journaliScienceen_US
dc.identifier.doi10.1016/j.isci.2020.101785
dc.identifier.cristin1846701
dc.relation.projectNorges forskningsråd: 226244en_US
dc.relation.projectNorges forskningsråd: 269408en_US
dc.description.localcodeThis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal